Changes in striatal D2-receptor density following chronic treatment with amphetamine as assessed with PET in nonhuman primates

Synapse

Volumn 31, Issue 2, 1999, Pages 154-162

  Ginovart, Nathalie ^a,b   Farde, Lars ^a   Halldin, Christer ^a   Swahn, Carl Gunnar ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b CERMEP IMAGERIE DU VIVANT   (France)

Author keywords

Amphetamine; Dopamine; Paranoid psychosis; Persisting stereotypes; Primate

Indexed keywords

AMPHETAMINE; DOPAMINE; DOPAMINE 2 RECEPTOR; DEXAMPHETAMINE; DIAGNOSTIC AGENT; DOPAMINE RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; PROLACTIN; RACLOPRIDE; SALICYLAMIDE DERIVATIVE;

ANIMAL EXPERIMENT; ARTICLE; BRAIN SCINTISCANNING; DOPAMINE BRAIN LEVEL; DOPAMINE RELEASE; DRUG EFFECT; DRUG RECEPTOR BINDING; ISOTOPE LABELING; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIMATE; PRIORITY JOURNAL; RECEPTOR DENSITY; STEREOTYPY; ANIMAL; ANIMAL BEHAVIOR; BLOOD; CEREBELLUM; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CORPUS STRIATUM; DOWN REGULATION; DRUG ABUSE; FEMALE; MACACA; METABOLISM; PSYCHOLOGICAL ASPECT; SCINTISCANNING;

AMPHETAMINE-RELATED DISORDERS; ANIMALS; BEHAVIOR, ANIMAL; CEREBELLUM; CORPUS STRIATUM; DEXTROAMPHETAMINE; DOPAMINE AGENTS; DOPAMINE ANTAGONISTS; DOWN-REGULATION; FEMALE; MACACA FASCICULARIS; PROLACTIN; RACLOPRIDE; RECEPTORS, DOPAMINE D2; SALICYLAMIDES; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0032588373     PISSN: 08874476     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2396(199902)31:2<154::AID-SYN9>3.0.CO;2-K     Document Type: Article

References (53)

1. Akiyama K, Sato M, Kashihara K, Otsuki S. 1982. Lasting changes in high affinity 3H-spiperone binding to the rat striatum and mesolimbic area after chronic methamphetamine administration: Evaluation of dopaminergic and serotoninergic receptor components. Biol Psychiatry 17:1389-1402.
2. Antelman SM, Chiodo LA. 1983. Amphetamine as a stressor In: Creese I, editor. Stimulants: Neurochemical, behavioral and clinical perspectives. New York: Raven Press, pp 269-299.
3. Azzaro AJ, Rutledge CO. 1973. Selectivity of release of norepinephrine, dopamine and 5-hydroxytryptamine by amphetamine in various regions of rat brain. Biochemical Pharmacol 22:2801-2813.
4. Bareggi SR, Gomeni R, Becker RE. 1978. Stereotyped behavior and hyperthermia in dogs: Correlation with the levels of amphetamine and p-hydroxyamphetamine in plasma and CSF. Psychopharmacology 58:89-94.
5. Bonhomme N, Cador M, Stinus L, Le Moal M, Spampinato U. 1995. Short and long-term changes in dopamine and serotonin receptor binding sites in amphetamine-sensitized rats: A quantitative autoradiographic study. Brain Res 675:215-223.
6. Breier A, Su TP, Saunders R, Carson RE, Kolachana BS, De Bartolomeis A, Weinberger DR, Weisenfeld N, Malhotra AK, Eckelman WC, Pickar D. 1997. Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: Evidence from a novel positron emission tomography method. Proc Natl Acad Sci USA 94:2569-2574.
7. Churchill AC, Burgess PM, Pead J, Gill T. 1993. Measurement of the severity of amphetamine dependence. Addiction 88:1335-1340.
8. Connell PH. 1958. Amphetamine psychosis. Maudsley Monograph No 5, Chapman and Hall, London: Oxford University Press.
9. 11C-raclopride is altered by drugs that modify synaptic dopamine levels. Synapse 13:350-356.
10. Ellinwood E, Sudilovsky A, Nelson L. 1973. Evolving behavior in the clinical and experimental amphetamine (model) psychosis. Am J Psychiatry 130:1088-1093.
11. Farde L, Hall H, Ehrin E, Sedvall G. 1986. Quantitative analysis of D2 dopamine receptor binding in the living human brain by PET. Science 231:258-261.
12. 2-dopamine receptors studied by PET - A comparison to the equilibrium analysis. J Cereb Blood Flow Metab 9:696-708.
13. 2-dopamine receptor characteristics in neuroleptic-naive patients with schizophrenia. Arch Gen Psychiatry 47: 213-219.
14. 2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine: Relation to extrapyramidal side effects. Arch Gen Psychiatry 49:538-544.
15. 11C]raclopride in man. Synapse 20:200-208.
16. Farde L, Gustavsson JP, Jönsson E. 1997. D2 dopamine receptors and personality traits. Nature 385:590.
17. Fuller RW, Baker JC, Molloy BB. 1977. Biological disposition of rigid analogs of amphetamine. J Pharm Sci 66:271-272.
18. 2-dopamine receptors in the monkey brain. Synapse 25:321-325.
19. 2 receptor binding. Nucl Med Biol 18:871-881.
20. Halldin C, Swahn CG, Farde L, Sedvall G. 1995. Radioligand disposition and metabolism - Key information in early drug development. In: Comar D, editor. PET for drug development and evaluation. Dordrecht: Kluwer Academic Publishers, pp 55-65.
21. Heikkila RE, Orlansky H, Mytilineau C, Cohen G. 1975. Amphetamine: Evaluation of d-and l-isomers as releasing agents and uptake inhibitors for 3H-dopamine and 3H-norepinephrine in slices of rat neostriatum and cerebral cortex. J Pharmacol Exp Ther 194:47-56.
22. Hume SP, Myers R, Bloomfield PM, Opacka-Juffry J, Cremer JE, Ahier RG, Luthra SK, Brooks DJ, Lammerstsma AA. 1992. Quantitation of carbon-11-labeled raclopride in rat striatum using positron emission tomography. Synapse 12:47-54.
23. Hutchaleelaha A, Sukbuntherng J, Chow HH, Mayersohn M. 1994. Disposition kinetics of d-and l-amphetamine following intravenous administration of racemic amphetamine to rats. Drug Metab Dispos 22:406-411.
24. 11C]raclopride binding. J Cereb Blood Flow Metab 18:941-950.
25. Jaber M, Cador M, Dumartin B, Normand E, Stinus L, Bloch B. 1995. Acute and chronic amphetamine treatments differently regulate neuropeptide messenger RNA levels and Fos immunoreactivity in rat striatal neurons. Neuroscience 65:1041-1050.
26. 11C]NNC 756 as new radioligands for the D1-dopamine receptor. Psychopharmacology 113:149-156.
27. Laruelle M, Abi-Dargham AA, Van Dick CH, Gil R, D'Douza CD, Erdos J, McCance E, Rosenblatt W, Fingado C, Zoghbi SS, Baldwin RM, Seibyl JP, Krystal JH, Charney DS, Innis RB. 1996. Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. Proc Natl Acad Sci USA 96:9235-9240.
28. Lillrank SM, Oja SS, Sarasaari P, Seppälä T. 1991. Animal models of amphetamine psychosis: Neurotransmitter release from rat brain slices. Int J Neurosci 60:1-15.
29. Litton J, Bergström M, Bohm C, Blomqvist G, Kesselberg M. 1984. Performance study of the PC-384 positron camera system for emission tomography of the brain. J Comput Assist Tomogr 8:74-87.
30. Melega WP, Williams AE, Schmitz DA, DiStefano EW, Cho AK. 1995. Pharmacokinetic and pharmacodynamic analysis of the actions of D-amphetamine and D-methamphetamine on the dopamine terminal. J Pharmacol Exp Ther 274:90-96.
31. Michiyama Y. 1992. Chronic methamphetamine intoxication model of schizophrenia in animals. Schizophr Bull 18:107-113.
32. Miller HH, Shore PA, Clarke DE. 1980. In vivo monoamine oxidase inhibition by d-amphetamine. Biochem Pharmacol 29:1347-1354.
33. 11C]raclopride binding in healthy young adults and schizophrenic patients - Reliability and age effects. Hum Psychopharmacol 7:157-165.
34. Paulson PE, Robinson TE. 1995. Amphetamine-induced time-dependent sensitization of dopamine neurotransmission in the dorsal and ventral striatum: A microdialysis study in behaving rats. Synapse 19:56-65.
35. Paulson PE, Camp DM, Robinson TE. 1991. Time course of transient behavioral depression and persistent behavioral sensitization in relation to regional brain monoamine concentrations during amphetamine withdrawal in rats. Psychopharmacology 103:480-492.
36. Randrup A, Munkvad I. 1965. Special antagonism of amphetamineinduced abnormal behavior. Inhibition of stereotyped activity with increase of some normal activities. Psychopharmacology 4:416-422.
37. Randrup A, Munkvad I. 1967. Stereotyped activities produced by amphetamine in several animal species and man. Psychopharmacology 11:300-310.
38. Robertson HA. 1982. Cerebral decortication reverses the effect of amphetamine on striatal D2 dopamine binding site density. Neurosci Lett 72:325-329.
39. Robertson HA. 1983. Chronic D-amphetamine and phencyclidine: Effects on dopamine agonist and antagonist binding sites in the extrapyramidal and mesolimbic systems. Brain Res 267:179-182.
40. Robinson TE, Becker JB. 1986. Enduring changes in brain and behavior produced by chronic amphetamine administration: A review and evaluation of animal models of amphetamine psychosis. Brain Res Rev 11:157-198.
41. Sato M, Numachi Y, Hamamura T. 1992. Relapse of paranoid psychotic state in methamphetamine model of schizophrenia. Schizophr Bull 18:115-122.
42. Snyder SH, Bannerjee S, Yamamura H, Greenberg D. 1974. Drugs, neurotransmitters and schizophrenia: Phenothiazines, amphetamine and enzymes synthesizing psychomimetic drugs and schizophrenia research. Science 184:1243-1253.
43. Tune L, Wong D, Pearlson G, Strauss M, Young T, Shaya EK, Dannals RF, Wilson AA, Ravert HT, Sapp J. 1993. Dopamine D2 receptor density estimates in schizophrenics: A positron emission tomography study with 11C-N-methyl-spiperone. Psychiatry Res 49:219-237.
44. Tune L, Barta P, Wong D, Powers RE, Pearlson G, Tien AY, Wagner HN. 1996. Striatal dopamine D2 receptor quantification and superior temporal gyrus: Volume determination in 14 chronic schizophrenic subjects. Psychiatry Res 67:155-158.
45. Ujike H, Onoue T, Akiyama K, Hamamura T, Otsuki S. 1989. Effects of selective D-1 and D-2 dopamine antagonists on development of methamphetamine-induced behavioral sensitization. Psychopharmacology 98:82-92.
46. Uretsky NJ, Snodgrass SR. 1977. Studies on the mechanism of stimulation of dopamine synthesis by amphetamine on striatal slices. J Pharmacol Exp Ther 202:565-580.
47. Van Rossum JM. 1966. The significance of dopamine receptor blockade for the mechanism of action of neuroleptic drugs. Arch Int Pharmacodyn 160:492-494.
48. Volkow ND, Fowler JS, Wolf AP, Schlyer D, Shiue CY, Alpert R, Dewey SL, Logan J, Bendriem B, Christman D, Hitzemann, Henn F. 1990. Effect of chronic cocaine abuse on postsynaptic dopamine receptors. Am J Psychiatry 147:719-724.
49. 11C]raclopride in the human brain. Synapse 16:255-262.
50. Watson R, Hartmann E, Schildkraut J. 1972. Amphetamine withdrawal: Affective state, sleep patterns, and MHPG excretion. Am J Psychiatry 129:263-269.
51. Wienhard K, Dahldom M, Eriksson L, Michel C, Bruckbauer T, Pietrzyk U, Heiss WD. 1994. The ECAT EXACT HR: Performance of a new high resolution positron scanner. J Comp Assist Tomogr 18:110-118.
52. Wolf ME, White FJ, Nassar R, Brooderson RJ, Khansa MR. 1993. Differential development of autoreceptor subsensitivity and enhanced dopamine release during amphetamine sensitization. J Pharmacol Exp Ther 264:249-255.
53. Wong DF, Wagner HN, Tune LE, Dannals RF, Pearlsson GD, Links JM, Tamminga CA, Broussole EP, Ravert HT, Wilson AA, Toung JKT, Malat J, Williams FA, O'Touma LA, Snyder SH, Kuhar MJ, Gjedde A. 1986. Positron emission tomography reveals elevated D2-dopamine receptors in drug-naive schizophrenics. Science 234: 1558-1563.